Irritable Bowel Disease (Crohn’s disease, Ulcerative Colitis)

HBOT is an incredible adjunct to conventional drugs by reducing acute and chronic inflammation; enhancing all stages of wound healing; Mobilizes stem cells and stimulates growth factors essential in tissue repair; modulates immune response; All while enhancing plasma oxygen up to 1200% to target tissue hypoxia – a key factor in IBD.

Limited high-quality evidence suggests that HBOT is safe and associated with substantial rates of clinical remission for multiple IBD phenotypes. Well-designed randomized controlled trials are warranted to confirm the benefit of HBOT in IBD.

Researchers have shown that more than 80% of patients with Crohn’s disease did report some improvement in their symptoms. Almost 50% of patients who had a fistula experienced full recovery.

A Review of Hyperbaric Oxygen Therapy for Inflammatory Bowel Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC8554584/

The Effectiveness and Safety of Hyperbaric Oxygen Therapy in Various Phenotypes of Inflammatory Bowel Disease: Systematic Review With Meta-analysis https://academic.oup.com/ibdjournal/article/28/4/611/6277724

The new insights of hyperbaric oxygen therapy: focus on inflammatory bowel disease https://academic.oup.com/pcm/article/7/1/pbae001/7577619

Hyperbaric oxygen therapy ameliorates intestinal and systematic inflammation by modulating dysbiosis of the gut microbiota in Crohn’s disease https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05317-1